ASAS-NSAID equivalent score
| NSAID | Dose comparable to 150 mg of diclofenac | Maximum dose used in AS | Consensus |
|---|---|---|---|
| Diclofenac | / | n=60* 150 (150–200) | 150 |
| Naproxen | n=57 | n=59 | n=47/50† |
| 1000 (1000–1000) | 1000 (1000–1500) | 1000 | |
| Aceclofenac | n=15 | n=14 | n=29/29 |
| 200 (200–200) | 200 (200–200) | 200 | |
| Celecoxib | n=61 | n=60 | n=47/50 |
| 400 (300–400) | 400 (400–400) | 400 | |
| Etodolac | n=15 | n=13 | n=17/20 |
| 600 (400–800) | 600 (600–600) | 600 | |
| Etoricoxib | n=36 | n=37 | n=42/46 |
| 90 (90–90) | 120 (90–120) | 90 | |
| Flurbiprofen | n=13 | n=13 | n=15/18 |
| 200 (200–300) | 300 (200–300) | 200 | |
| Ibuprofen | n=54 | n=54 | n=39/45 |
| 2400 (1600–2400) | 2400 (2400–2400) | 2400 | |
| Indometacin | n=57 | n=58 | n=42/47 |
| 150 (100–150) | 150 (150–200) | 150 | |
| Ketoprofen | n=26 | n=25 | n=21/23 |
| 200 (200–200) | 200 (200–300) | 200 | |
| Meloxicam | n=58 | n=55 | n=42/48 |
| 15 (15–15) | 15 (15–22.5) | 15 | |
| Nimesulide | n=8 | n=9 | n=16/16 |
| 200 (200–200) | 200 (200–200) | 200 | |
| Phenylbutazone | n=28 | n=28 | n=25/28 |
| 400 (200–500) | 400 (250–600) | 400 | |
| Piroxicam | n=51 | n=50 | n=46/46 |
| 20 (20–20) | 20 (20–40) | 20 | |
| Tenoxicam | n=17 | n=16 | n=18/18 |
| 20 (20–20) | 25 (20–40) | 20 |
Results of the survey evaluating the opinion of ASAS members about the comparable efficacy of each NSAID with 150 mg of diclofenac.
Values given are:
↵* first row, n=number of ASAS members giving an answer to the question; second row, median dose in mg (tertiles).
↵† first row, n=number of ASAS members who have voted in favour of such a dose/the total number of ASAS members who have voted; second row, agreed dose.
AS, ankylosing spondylitis; ASAS, Assessment of Spondyloarthritis International Society; NSAID, non-steroidal anti-inflammatory drug.